NEW HYPOLIPAEMIC AGENTS DESIGNED BY MOLECULAR TOPOLOGY : PHARMACOLOGICAL STUDIES OF 2,6-DI-TERT-BUTYL-4-METHYLPYRIDINE AND 2,6-DI-TERT-BUTYLPYRIDINE

Abstract

New compounds showing hypolipaemic activity have been designed using a computer-aided method based on molecular topology and QSAR analysis. Linear discriminant analysis and connectivity functions were used to design three potentially suitable drugs which were tested for hypolipaemic properties by the Triton WR-1339 test in rats. The pharmacological tests carried out on the newly designed compounds demonstrated the existence of notable activity in phase I for two of them. namely 2,6-Di-tert-butyl-4-methylpyridine (C.A.S. 38222-83-2) and 2,6-Di-tert-butylpyridine (C.A.S. 585-48-8), with respect to the level of total cholesterol. Both substances decrease the lipaemia to lower levels than clofibrate, which was used as a reference drug.